Esmolol potentiates reduction of minimum alveolar isoflurane concentration by alfentanil

Anesthesia and Analgesia

Volumn 87, Issue 3, 1998, Pages 671-676

  Johansen, Jay W ^a,b   Schneider, Gerhard ^a   Windsor, Alastair M ^a   Sebel, Peter S ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALFENTANIL; ESMOLOL; ISOFLURANE; PROPOFOL;

ADULT; AGED; ARTICLE; DRUG POTENTIATION; FEMALE; HEART RATE; HUMAN; INHALATION ANESTHESIA; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MINIMUM LUNG ALVEOLUS CONCENTRATION; PRIORITY JOURNAL;

EID: 0031679203     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/00000539-199809000-00034     Document Type: Article

References (35)

1. Eger EI II, Saidman LJ, Brandstater B. Minimum alveolar anesthetic concentration: a standard of anesthetic potency. Anesthesiology 1965;26:756-63.
2. Quasha AL, Eger EI II, Tinker JH. Determination and applications of MAC. Anesthesiology 1980;53:315-34.
3. Glass PS, Doherty M, Jacobs JR, et al. Plasma concentration of fentanyl, with 70% nitrous oxide, to prevent movement at skin incision. Anesthesiology 1993;78:842-7.
4. 50 by fentanyl. Anesthesiology 1992;77:A340.
5. Tsunoda Y, Hattori Y, Takatsuka E, et al. Effects of hydroxyzine, diazepam, and pentazocine on halothane minimum alveolar anesthetic concentration. Anesth Analg 1973;52:390-4.
6. Forbes AR, Cohen NH, Eger EI II. Pancuronium reduces halothane requirement in man. Anesth Analg 1979;58:497-9.
7. Murray DJ, Mehta MP, Forbes RB, Dull DL. Additive contribution of nitrous oxide to halothane MAC in infants and children. Anesth Analg 1990;71:120-4.
8. Sebel PS, Glass PS, Fletcher JE, et al. Reduction of the MAC of desflurane with fentanyl. Anesthesiology 1992;76:52-9.
9. McEwan AI, Smith C, Dyar O, et al. Isoflurane minimum alveolar concentration reduction by fentanyl. Anesthesiology 1993; 78:864-9.
10. Westmoreland CL, Sebel PS, Gropper A. Fentanyl or alfentanil decreases the minimum alveolar anesthetic concentration of isoflurane in surgical patients. Anesth Analg 1994;78:23-8.
11. Johansen JW, Flaishon R, Sebel PS. Esmolol reduces anesthetic requirement for skin incision during propofol/nitrous oxide/ morphine anesthesia. Anesthesiology 1997;86:364-71.
12. Gold MI, Elliott BA. Clinical applications of esmolol during noncardiac surgery. J Cardiothorac Anesth 1990;4:22-6.
13. Gold MI, Sacks DJ, Grosnoff DB, et al. Use of esmolol during anesthesia to treat tachycardia and hypertension. Anesth Analg 1989;68:101-4.
14. Murthy VS, Hwang TF, Sandage BW, Laddu AR. Esmolol and the adrenergic response to perioperative stimuli. J Clin Pharmacol 1986;26:A27-35.
15. Reves JG, Flezzani P. Perioperative use of esmolol. Am J Cardiol 1985;56:57F-62F.
16. Scott JC, Stanski DR. Decreased fentanyl and alfentanil dose requirements with age: a simultaneous pharmacokinetic and pharmacodynamic evaluation. J Pharmacol Exp Ther 1987;240: 159-66.
17. Hall RI, Szlam F, Hug CC Jr. The enflurane-sparing effect of alfentanil in dogs. Anesth Analg 1987;66:1287-91.
18. Dixon WJ. The up-and-down method for small samples. Am Stat Assoc 1965;60:966-78.
19. Merkel G, Eger EI II. A comparative study of halothane and halopropane anesthesia. Anesthesiology 1963;24:346-57.
20. Saidman LJ, Eger EI II. Effect of nitrous oxide and of narcotic premedication on the alveolar concentration of halothane required for anesthesia. Anesthesiology 1964;25:302-6.
21. Scott JC, Ponganis KV, Stanski DR. EEG quantitation of narcotic effect: the comparative pharmacodynamics of fentanyl and alfentanil. Anesthesiology 1985;62:234-41.
22. Stevens WC, Dolan WM, Gibbons RT, et al. Minimum alveolar concentrations (MAC) of isoflurane with and without nitrous oxide in patients of various ages. Anesthesiology 1975;42: 197-200.
23. Tanifuji Y, Eger EI II. Effect of isoproterenol and propranolol on halothane MAC in dogs. Anesth Analg 1976;55:383-7.
24. Stanley TH, de Lange S, Boscoe MJ, de Bruijn N. The influence of chronic preoperative propranolol therapy on cardiovascular dynamics and narcotic requirements during operation in patients with coronary artery disease. Can Anaesth Soc 1982;29: 319-24.
25. Baranov D, Bagshaw RJ. Possible interaction of esmolol and nitrous oxide. Anesthesiology 1997;87:461-2.
26. Waud BE, Waud DR. On dose-response curves and anesthetics. Anesthesiology 1970;33:1-4.
27. Greco WR, Bravo G, Parsons JC. The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 1995;47:331-85.
28. Murmann W, Almirante L, Saccani-Guelfi M. Central nervous system effects of four beta-adrenergic receptor blocking agents. Pharmac Pharmacol 1966;18:317-8.
29. Bainbridge JG, Greenwood DT. Tranquilizing effects of propranolol demonstrated in rats. Neuropharmacology 1971;10: 453-8.
30. Leszkovszky G, Tardos L. Some effects of propranolol on the central nervous system. Pharmac Pharmacol 1965;17:518-9.
31. Murmann W, Almirante L, Saccani-Guelfi M. Effects of hexobarbitone, ether, morphine, and urethane upon the acute toxicity of propranolol and D-(-)-INPEA. Pharmac Pharmacol 1966; 18:692-4.
32. Gorczynski RJ. Basic pharmacology of esmolol. Am J Cardiol 1985;56:3F-13F.
33. Angaran DM, Schultz NJ, Tschida VH. Esmolol hydrochloride: an ultrashort-acting, beta-adrenergic blocking agent. Clin Pharm 1986;5:288-303.
34. Sum CY, Yacobi A, Kartzinel R, et al. Kinetics of esmolol, an ultra-short-acting beta blocker, and of its major metabolite. Clin Pharmacol Ther 1983;34:427-34.
35. Wood AJ, Feely J. Pharmacokinetic drug interactions with propranolol. Clin Pharmacokinet 1983;8:253-62.